AMPLIFICATION OF SELF PROCESSING RNA VECTORS IN PLANTS

我们提出了一种大规模生产定制RNA的新方法 使用植物病毒RNA载体的产品。这种节能、低成本 而环境友好的方法将产生长RNA分子 (不能通过化学合成获得的)比 体内和体外可选择的转录系统。所需的RNA 在实验室中插入RNA载体并扩增的片段 通过病毒的生物循环，仅仅几天后 在受感染的植物中孵化，很容易分离出病毒粒子 (它防止了RNA的降解，是一种理想的存储形式)。之后 从病毒粒子外壳蛋白中简单分离嵌合病毒RNA 亚单位，所需的RNA片段将被切割和分离 从其余的病毒RNA中分离出来。为此，我们建议写一部小说 盒式设计，其中所需的RNA片段位于RNA载体内 侧翼有两个潜在的核酶(在体内不活跃)，它将 不会影响病毒的放大。它们在体外激活后 嵌合RNA的分离将通过孵育完成。 在未在体内呈现的溶液环境中。 建议的商业应用： RNA是结构生物学和生物医学研究的重要靶点 包括艾滋病毒和流感病毒。它也有潜在的反义作用。 核酶疗法、生物技术产品和分子生物学 工具。我们的技术将以更少的成本提供大量的定制RNA 比其他方法成本更高，效率更高。我们目前的情况 商业战略是将这项新技术授权给更大的公司 比如Biosource Technologies。

We propose a novel approach to large-scale production of custom RNA products using plant viral RNA vectors. This energy efficient, low cost and environmentally friendly method would generate long RNA molecules (not available through chemical synthesis) less expensively than alternative in vivo and in vitro transcription systems. the desired RNA fragment inserted in the laboratory into the RNA vector and amplified through the viral biological cycles could then, after only a few days' incubation in infected plants, be easily isolated as virion particles (which preclude RNA degradation and are an ideal storage form). after simple separation of chimeric viral RNA from the virion coat protein subunits, the desired RNA fragment would be cleaved out and separated from the rest of the viral RNA. For this purpose we suggest a novel cassette design where the desired RNA fragment within the RNA vector would be flanked by two latent ribozymes (inactive in vivo), which will not compromise the virus amplification. Their activation in vitro after isolation of the chimeric RNA will be accomplished through incubation in a solution environment not presented in vivo. PROPOSED COMMERCIAL APPLICATION: RNA is an important target for structural biology and biomedical studies including HIV and influenza viruses. It also has potential in antisense and ribozyme therapeutics, biotechnology products and molecular biology tools. Our technology would provide large amounts of custom RNAs less expensively and more efficiently than alternative methods. Our current business strategy is to license this new technology to larger companies such as Biosource Technologies.